The "TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook 2026" report has been added to ResearchAndMarkets.com's offering. This report tracks developments currently taking place ...

The report on Uveitis clinical trials highlights opportunities in understanding trial count, enrollment trends, and successful trial regions. It aids strategic investment decisions by identifying key ...

To keep research teams informed of the latest updates to ClinicalTrials.gov, the University at Buffalo Clinical and Translational Science Institute (CTSI) will be providing news about the ...

Clinical Trial Investigative Site Network Market was valued at USD 9.2 Bn in 2025 and is projected to reach USD 18.7 Bn by ...

CTSI Open Research Office sessions feature important topics that can aid those involved in the research process. Through the Open Research Office sessions, Clinical Research Facilitators collaborate ...

(MENAFN- GlobeNewsWire - Nasdaq) The TIGIT inhibitors market is poised for growth with the anticipated drug approval by 2030, over 40 drugs in clinical trials, and a dynamic landscape involving major ...

The main market opportunities lie in developing precise CD22 targeted therapies for blood cancers, with over 20 ongoing clinical trials. Innovative technologies like TALEN® are enhancing cell-based ...

CNSide Diagnostics will present data from the FORESEE trial showcasing the CNSide CSF Assay Platform’s utility in diagnosing and guiding clinical decision making for breast cancer and non-small cell ...

AUSTIN, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (PSTV) (Nasdaq: PSTV) (“Plus” or the “Company”), will present data from ...

The report identifies opportunities in optimizing clinical trial strategies and locations, highlighting key market positions in cholera research. It aids in strategy formulation by providing insights ...